Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540992 | 1.00 | DKK1 (0.65) | DKK1HRH3FAAHRAD52KCNH2 | |
| SCHEMBL3645499 | 1.00 | DKK1 (0.65) | DKK1HRH3FAAHRAD52KCNH2 | |
| SCHEMBL3645495 | 1.00 | DKK1 (0.65) | DKK1HRH3FAAHRAD52KCNH2 | |
| SCHEMBL3652034 | 1.00 | DKK1 (0.65) | DKK1HRH3FAAHRAD52KCNH2 | |
| SCHEMBL3645336 | 0.99 | DKK1 (0.66) | DKK1HRH3FAAHRAD52JAK2 | |
| SCHEMBL4538908 | 0.99 | DKK1 (0.66) | DKK1HRH3FAAHRAD52JAK2 | |
| SCHEMBL4540878 | 0.99 | DKK1 (0.66) | DKK1HRH3FAAHRAD52JAK2 | |
| SCHEMBL4537787 | 0.94 | DKK1 (0.60) | DKK1HRH3FAAHRAD52 | |
| SCHEMBL3648064 | 0.90 | DKK1 (0.64) | DKK1FAAHPIK3CA | |
| SCHEMBL4532479 | 0.90 | DKK1 (0.64) | DKK1FAAHPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | claimed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | DKK1 9/4885HRH3 3526/4885FAAH 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.